Management is buying the same thing twice: proven demand from one place is being replicated into identified new places r
The model's full reasoning — Q3 2018 call → NOWe need to determine if management describes a situation where a proven instance is being replicated now, with demand already visible at the destination. The key is: a specific, identifiable piece of the company that has been proven in real operation, and the company is currently standing up further instances of that same piece in other places, with demand already identified. Scan the transcript for such descriptions. Management discusses various launches, expansions, but we need a clear case of replication of a proven unit. For example, Dupixent is being launched in new countries, but is that a replication of a proven instance? The drug is proven, but the "instance" might be the launch in a new market. However, the question asks about copying a part of its own business that is already working into additional places where the same demand is already visible. That could be like opening new manufacturing plants, new sales territories, etc. Look for phrases like "we are now expanding", "we are rolling out", "we are replicating", "we are opening additional". Also, demand already visible: e.g., "we have a waiting list", "customers are asking", "we are turning away business". In the transcript, there is discussion about Pentaxim in China, but that's about supply recovery, not replication. There is discussion about launching Dupixent in new countries, but that's a product launch, not necessarily a replication of a proven business unit. The question is about a "part of its own business" that is being copied. For example, if they have a successful manufacturing process and are building new plants to meet demand. Consider the Vaccines business: they are expanding? Not really. Consider the CHC business: they acquired BI CHC, but that's not replication. Consider the new GBU structure: that's reorganization, not replication. Consider the launches of new products: that's not replication of a proven instance.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| PUMP | ProPetro Holding Corp. | Q4 2023 | 2024-02-21 | C+ |
| BRBR | BellRing Brands, Inc. | Q4 2023 | 2023-11-21 | B+ |
| SYY | Sysco Corporation | Q1 2023 | 2022-11-01 | C+ |
| VSEC | VSE Corporation | Q3 2022 | 2022-10-28 | B+ |
| FSLR | First Solar, Inc. | Q3 2022 | 2022-10-28 | C+ |
| CRL | Charles River Laboratories International | Q2 2022 | 2022-08-03 | C |
| SYM | Symbotic Inc. | Q3 2022 | 2022-08-01 | B+ |
| GDS | GDS Holdings Limited | Q2 2021 | 2021-08-17 | C+ |
| TPIC | TPI Composites, Inc. | Q3 2018 | 2018-11-11 | C |
| ALB | Albemarle Corporation | Q3 2018 | 2018-11-08 | B |
| IRT | Independence Realty Trust, Inc. | Q2 2018 | 2018-08-02 | B |
| FOLD | Amicus Therapeutics, Inc. | Q1 2018 | 2018-05-08 | C+ |
| AOSL | Alpha and Omega Semiconductor Limited | Q2 2018 | 2018-02-07 | B |
| VSAT | Viasat, Inc. | Q4 2017 | 2017-05-23 | C+ |
| PLAB | Photronics, Inc. | Q2 2017 | 2017-05-17 | C+ |
| GOGO | Gogo Inc. | Q1 2016 | 2016-05-06 | C+ |
GDS · Q2 2021 → YESThe question is whether management describes the company as currently in the middle of copying a part of its own business that is already working into additional places where the same demand is alread...YES The transcript shows management describing a clear, present-tense replication of their proven China-based data center platform into new markets (Hong Kong, Macau, Southeast Asia) where demand is already visible and committed. William Huang explicitly references the “proven” China edge-of-town model (land-and-expand MOUs, 500 000 sqm secured pipeline, hyperscale orders already landed) and states they are “currently developing two purpose-built data centers” in Hong Kong (HK1/HK2) with most capacity “already allocated to strategic customers pending contracts,” plus a new building (HK4) under agreement and a heads-of-agreement for HK3, creating “nearly 80 megawatts of purpose-built capacity through to 2027.” For Macau they have a JV to acquire brownfield sites for redevelopment (20 MW).
FOLD · Q1 2018 → YESThe question is about whether management describes the company as currently copying a proven part of its business into additional places where demand is already visible. YES The transcript shows management describing Galafold as a proven commercial offering (Q1 revenue $16.7M, 300% YoY growth, hundreds of patients, high compliance, 7 approvals, 18 countries with pricing/reimbursement) that is now being replicated into additional markets.
TPIC · Q3 2018 → YESThe question is whether management describes the company as currently in the middle of copying a part of its own business that is already working into additional places where the same demand is alread...YES The transcript shows management describing a proven manufacturing operation (existing dedicated lines and plants in the U.S.